SynthesisEuropean journal of medical research2025
Prevalence, characteristics, and treatment outcomes of epilepsy in Nigeria: a systematic review and meta-analysis.
Synthesis in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stroke in Ghana: A Situational Analysis.Stroke research and treatment · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpilepsy poses a significant health burden globally. In Nigeria, limited access to healthcare and potential regional variations in risk factors necessitate an understanding of epilepsy's characteristics and treatment. This study addresses this gap by conducting a systematic review and meta-analysis to investigate the prevalence, demographic variations, seizure types, and treatment modalities of epilepsy in Nigeria.
methodsA systematic review was conducted following PRISMA guidelines (CRD42024549637). We searched PubMed, Google Scholar, and other databases (6 total) from inception to February 2024 using a combination of MeSH terms and keywords related to epilepsy and Nigeria. Studies included observational studies, clinical trials, and those reporting on the prevalence, characteristics, and management of epilepsy in Nigeria. We excluded studies outside Nigeria, lacking relevant data, or non-research materials. Two reviewers screened titles/abstracts and full texts for eligibility. Data extraction included demographics, sample size, location, seizure type, and treatment outcomes. The JBI tool assessed study quality. We did systematic synthesis and meta-analysis for prevalence.
resultsThe prevalence of epilepsy ranged from 0.45 to 36.09%. The overall pooled prevalence of epilepsy is 14.21% (95% CI 1.56-36.16) among all age group patients. Children presented with the highest prevalence (36.09%), followed by adults (11.85%) and in combine adult and children studies (3.16%). The South-South zone had the highest prevalence (21.73%), while the North-Central zone had the lowest (0.47%). Generalized tonic-clonic seizures were the most common type reported (76.9-83.13%). Carbamazepine was a frequent first-line treatment, with some studies indicating good results, particularly in children. Monotherapy was generally preferred.
conclusionEpilepsy prevalence in Nigeria varies considerably. Children and the South-South zone appear to be more affected. Carbamazepine is a common first-line treatment. Further research is required to explore underlying causes, optimal treatment strategies, and adherence challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.